Pathogenesis and treatment of atherosclerosis in lupus

Rheumatic Disease Clinics of North America

Volumn 40, Issue 3, 2014, Pages 475-495

  McMahon, Maureen ^a   Skaggs, Brian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Cytokine; Proinflammatory lipids; Systemic lupus erythematosus

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMALARIAL AGENT; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; SIMVASTATIN; THIAZIDE DIURETIC AGENT; BIOLOGICAL MARKER; CYTOKINE;

ACUTE PHASE RESPONSE; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE DURATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART DISEASE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLEPTINEMIA; HYPERTENSION; INFLAMMATION; LIPID PEROXIDATION; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; AGE; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE MANAGEMENT; LIPID METABOLISM; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; OUTCOME ASSESSMENT; PREVALENCE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

AGE FACTORS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYTOKINES; DISEASE MANAGEMENT; HUMANS; LIPID METABOLISM; LUPUS ERYTHEMATOSUS, SYSTEMIC; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84904405710     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.04.003     Document Type: Review

References (153)

1. Urowitz M.B., Bookman A.A., Koehler B.E., et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60(2):221-225.
2. Abu-Shakra M., Urowitz M.B., Gladman D.D., et al. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. JRheumatol 1995, 22(7):1265-1270.
3. Schoenfeld S.R., Kasturi S., Costenbader K.H. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013, 43(1):77-95.
4. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145(5):408-415.
5. Shah M.A., Shah A.M., Krishnan E. Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. JRheumatol 2009, 36(3):570-575.
6. Bernatsky S., Boivin J.F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2550-2557.
7. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12(3):204-212.
8. Hunt B.J. The endothelium in atherogenesis. Lupus 2000, 9(3):189-193.
9. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145(3):341-355.
10. Navab M., Reddy S.T., Van Lenten B.J., et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8(4):222-232.
11. Van Lenten B.J., Hama S.Y., de Beer F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. JClin Invest 1995, 96(6):2758-2767.
12. McMahon M., Grossman J., FitzGerald J., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006, 54(8):2541-2549.
13. Gladman D.D., Urowitz M.B. Morbidity in systemic lupus erythematosus. JRheumatol 1987, 14(Suppl 13):223-226.
14. Aranow C., Ginzler E.M. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000, 9(3):166-169.
15. Petri M., Perez-Gutthann S., Spence D., et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992, 93(5):513-519.
16. Toloza S.M., Uribe A.G., McGwin G., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50(12):3947-3957.
17. Urowitz M.B., Gladman D., Ibanez D., et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007, 16(9):731-735.
18. Rahman P., Gladman D.D., Urowitz M.B. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. JRheumatol 1998, 25(9):1716-1719.
19. Jung H., Bobba R., Su J., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62(3):863-868.
20. Henkin Y., Como J.A., Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 1992, 267(7):961-968.
21. Borba E.F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997, 6(6):533-539.
22. Esdaile J.M., Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44(10):2331-2337.
23. Chung C.P., Oeser A., Avalos I., et al. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006, 15(9):562-569.
24. Bruce I.N., Urowitz M.B., Gladman D.D., et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003, 48(11):3159-3167.
25. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000, 26(2):199-213. v.
26. Cervera R., Khamashta M.A., Font J., et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999, 78(3):167-175.
27. Urowitz M.B., Gladman D., Ibanez D., et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010, 62(6):881-887.
28. Touma Z., Gladman D.D., Ibanez D., et al. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. Rheumatology (Oxford) 2012, 51(3):528-534.
29. Nikpour M., Urowitz M.B., Ibanez D., et al. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther 2011, 13(5):R156.
30. Bengtsson C., Ohman M.L., Nived O., et al. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 2012, 21(4):452-459.
31. Romero-Diaz J., Vargas-Vorackova F., Kimura-Hayama E., et al. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) 2011, 51(1):110-119.
32. Manzi S., Seizer F., Sutton-Tyrrell K., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42(1):51-60.
33. Roman M.J., Crow M.K., Lockshin M.D., et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007, 56(10):3412-3419.
34. Kiani A.N., Post W.S., Magder L.S., et al. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011, 50(11):2071-2079.
35. McMahon M., Skaggs B.J., Grossman J.M., et al. Apanel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol 2014, 66(1):130-139.
36. Sule S., Fivush B., Neu A., et al. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol 2011, 26(1):93-98.
37. Von Feldt J.M., Scalzi L.V., Cucchiara A.J., et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54(7):2220-2227.
38. Schanberg L.E., Sandborg C., Barnhart H.X., et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009, 60(5):1496-1507.
39. Doria A., Shoenfeld Y., Wu R., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62(11):1071-1077.
40. Norby G.E., Gunther A., Mjoen G., et al. Prevalence and risk factors for coronary artery calcification following kidney transplantation for systemic lupus erythematosus. Rheumatology (Oxford) 2011, 50(9):1659-1664.
41. McMahon M., Grossman J., Skaggs B., et al. Dysfunctional pro-inflammatory high density lipoproteins confer increased risk for atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009, 60(8):2428-2437.
42. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003, 349(25):2399-2406.
43. Thompson T., Sulton-Tyrrell K., Wildman R.P., et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008, 58(3):835-842.
44. Rua-Figueroa I., Arencibia-Mireles O., Elvira M., et al. The factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a two year longitudinal study. Ann Rheum Dis 2009, 69(6):1136-1139.
45. Manger K., Kusus M., Forster C., et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003, 62(9):846-850.
46. Haque S., Gordon C., Isenberg D., et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. JRheumatol 2010, 37(2):322-329.
47. Lertratanakul A., Wu P., Dyer A.R., et al. Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013, [Epub ahead of print].
48. Urbanus R.T., Siegerink B., Roest M., et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009, 8(11):998-1005.
49. Toloza S.M., Roseman J.M., Alarcon G.S., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004, 50(10):3177-3186.
50. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010, 19(4):419-423.
51. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003, 349(25):2407-2415.
52. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103(13):1813-1818.
53. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998, 18(9):1386-1392.
54. Yeh E.T. CRP as a mediator of disease. Circulation 2004, 109(21 Suppl 1):II11-II14.
55. Pasceri V., Cheng J.S., Willerson J.T., et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103(21):2531-2534.
56. Pons-Estel G.J., Gonzalez L.A., Zhang J., et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) 2009, 48(7):817-822.
57. Gustafsson J.T., Simard J.F., Gunnarsson I., et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012, 14(2):R46.
58. Selzer F., Sulton-Tyrrell K., Fitzgerald S.G., et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004, 50(1):151-159.
59. Rho Y.H., Chung C.P., Oeser A., et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009, 61(11):1580-1585.
60. Charakida M., Besler C., Batuca J.R., et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009, 302(11):1210-1217.
61. Navab M., Hama S.Y., Anantharamaiah G.M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. JLipid Res 2000, 41(9):1495-1508.
62. Delgado Alves J., Ames P.R., Donohue S., et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002, 46(10):2686-2694.
63. Batuca J.R., Ames P.R., Isenberg D.A., et al. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:137-146.
64. Kiss E., Seres I., Tarr T., et al. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:83-91.
65. Sweeney G. Cardiovascular effects of leptin. Nat Rev Cardiol 2010, 7(1):22-29.
66. Anderson P.D., Mehta N.N., Wolfe M.L., et al. Innate immunity modulates adipokines in humans. JClin Endocrinol Metab 2007, 92(6):2272-2279.
67. Garcia-Gonzalez A., Gonzalez-Lopez L., Valera-Gonzalez I.C., et al. Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int 2002, 22(4):138-141.
68. Wislowska M., Rok M., Stepien K., et al. Serum leptin in systemic lupus erythematosus. Rheumatol Int 2008, 28(5):467-473.
69. Sada K.E., Yamasaki Y., Maruyama M., et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. JRheumatol 2006, 33(8):1545-1552.
70. Al M., Ng L., Tyrrell P., et al. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48(5):497-501.
71. McMahon M., Skaggs B.J., Sahakian L., et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 2011, 70(9):1619-1624.
72. Reynolds H.R., Buyon J., Kim M., et al. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis 2010, 210(2):569-574.
73. Chung C., Long A., Salus J., et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009, 18(9):799-806.
74. Malinow M.R., Nieto F.J., Szklo M., et al. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993, 87(4):1107-1113.
75. Wall R.T., Harlan J.M., Harker L.A., et al. Homocysteine-induced endothelial cell injury invitro: a model for the study of vascular injury. Thromb Res 1980, 18(1-2):113-121.
76. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. JClin Invest 1993, 91(1):308-318.
77. Poddar R., Sivasubramanian N., DiBello P.M., et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001, 103(22):2717-2723.
78. McCully K.S. Homocysteine and vascular disease. Nat Med 1996, 2(4):386-389.
79. Hajjar K.A. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. JClin Invest 1993, 91(6):2873-2879.
80. Gerhard G.T., Duell P.B. Homocysteine and atherosclerosis. Curr Opin Lipidol 1999, 10(5):417-428.
81. Potter K., Hankey G.J., Green D.J., et al. Homocysteine or renal impairment: which is the real cardiovascular risk factor?. Arterioscler Thromb Vasc Biol 2008, 28(6):1158-1164.
82. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996, 25(4):191-193.
83. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000, 9(3):170-175.
84. Svenungsson E., Jensen-Urstad K., Heimburger M., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104(16):1887-1893.
85. Refai T.M., AI-Salem I.H., Nkansa-Dwamena D., et al. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 2002, 21(6):457-461.
86. Kao A.H., Lertratanakul A., Elliott J.R., et al. Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol 2013, 112(7):1025-1032.
87. Nikpour M., Gladman D.D., Ibanez D., et al. Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. JRheumatol 2009, 36(2):288-294.
88. El-Magadmi M., Bodill H., Ahmad Y., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004, 110(4):399-404.
89. Oeser A., Chung C.P., Asanuma Y., et al. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005, 52(11):3651-3659.
90. Ishimori M.L., Martin R., Berman D.S., et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging 2011, 4(1):27-33.
91. Kiani A.N., Petri M. Quality-of-life measurements versus disease activity in systemic lupus erythematosus. Curr Rheumatol Rep 2010, 12(4):250-258.
92. Kiani A.N., Mahoney J.A., Petri M. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. JRheumatol 2007, 34(7):1502-1505.
93. Avalos I., Chung C.P., Oeser A., et al. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus 2007, 16(12):981-986.
94. Costenbader K.H., Brome D., Blanch D., et al. Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study. Arthritis Rheum 2007, 57(1):49-55.
95. Haque S., Bruce I.N. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2005, 2(8):423-430.
96. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
97. Costenbader K.H., Karlson E.W., Gall V., et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum 2005, 53(5):718-723.
98. Duran-Barragan S., McGwin G., Vila L.M., et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 2008, 47(7):1093-1096.
99. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69(2):325-331.
100. Ravenell R.L., Kamen D.L., Spence J.D., et al. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci 2012, 344(4):268-273.
101. Kitamura N., Matsukawa Y., Takei M., et al. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis. JInt Med Res 2009, 37(3):892-898.
102. Vedove C.D., Del Giglio M., Schena D., et al. Drug-induced lupus erythematosus. Arch Dermatol Res 2009, 301(1):99-105.
103. Aizer J., Karlson E.W., Chibnik L.B., et al. Acontrolled comparison of brachial artery flow mediated dilation (FMD) and digital pulse amplitude tonometry (PAT) in the assessment of endothelial function in systemic lupus erythematosus. Lupus 2009, 18(3):235-242.
104. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. NEngl J Med 1995, 333(20):1301-1307.
105. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl 2004, 5(3):91-97.
106. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279(20):1615-1622.
107. Chen C.H., Jiang W., Via D.P., et al. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 2000, 101(2):171-177.
108. Leung B.P., Sattar N., Crilly A., et al. Anovel anti-inflammatory role for simvastatin in inflammatory arthritis. JImmunol 2003, 170(3):1524-1530.
109. Xu Z.M., Zhao S.P., Li Q.Z., et al. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003, 338(1-2):17-24.
110. Costenbader K.H., Liang M.H., Chibnik L.B., et al. Apravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007, 27(11):1071-1077.
111. Aprahamian T., Bonegio R., Rizzo J., et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. JImmunol 2006, 177(5):3028-3034.
112. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92(7):1758-1764.
113. Grundy S.M., Gleeman J.l., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239.
114. Willis R., Seif A.M., McGwin G., et al. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort. Clin Exp Rheumatol 2014, 32(2):162-167.
115. Plazak W., Gryga K., Dziedzic H., et al. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011, 13(4):R117.
116. Ferreira G.A., Navarro T.P., Telles R.W., et al. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007, 46(10):1560-1565.
117. Petri M., Kiani A., Post W., et al. Lupus atherosclerosis prevention study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 2006, 54(9):S520.
118. Schanberg L.E., Sandborg C., Barnhart H.X., et al. Does Atorvastatin Reduce Progression of Carotid Intimal Medial Thickening (CIMT) in Childhood SLE? Results from the Atherosclerosis Prevention in Pediatric Lupus (APPLE) Trial: a Multicenter, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Rheum 2010, 62(Suppl):1677.
119. Kang S., Wu Y., Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 2004, 177(2):433-442.
120. Stone N.J., Bilek S., Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III Update: adjustments and options. Am J Cardiol 2005, 96(4A):53-59.
121. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.l., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15(9):577-583.
122. Alarcon G.S., McGwin G., Bertoli A.M., et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007, 66(9):1168-1172.
123. Rahman P., Gladman D.D., Urowitz M.B., et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. JRheumatol 1999, 26(2):325-330.
124. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(Suppl 1):S16-S22.
125. Penn S.K., Kao A.H., Schott L.L., et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. JRheumatol 2010, 37(6):1136-1142.
126. Wallace D.J. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?. Arthritis Rheum 1987, 30(12):1435-1436.
127. Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009, 68(2):238-241.
128. Selzer F., Sulton-Tyrrell K., Fitzgerald S., et al. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001, 37(4):1075-1082.
129. Sun S., Rao N.L., Venable J., et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007, 6(4):223-235.
130. Mann J.F., Sheridan P., McQueen M.J., et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Nephrol Dial Transplant 2008, 23(2):645-653.
131. Liang M.H., Mandl L.A., Costenbader K., et al. Atherosclerotic vascular disease in systemic lupus erythematosus. JNatl Med Assoc 2002, 94(9):813-819.
132. Petri M., Spence D., Bone L.R., et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992, 71(5):291-302.
133. Takaoka T., Sarukura N., Ueda C., et al. Effects of zinc supplementation on serum zinc concentration and ratio of apo/holo-activities of angiotensin converting enzyme in patients with taste impairment. Auris Nasus Larynx 2010, 37(2):190-194.
134. Richez C., Richards R.J., Duffau P., et al. The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. PLoS One 2013, 8(4):e61042.
135. Chung C.P., Salus J.F., Oeser A., et al. N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: relationship with inflammation, augmentation index, and coronary calcification. JRheumatol 2008, 35(7):1314-1319.
136. Gibson W.T., Hayden M.R. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci 2007, 1110:209-221.
137. Svensson P., de Faire U., Sleight P., et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001, 38(6):E28-E32.
138. Yusuf S. Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study. Eur Heart J 2001, 22(2):103-104.
139. McInnes I.B., Thompson L., Giles J.T., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2013, [Epub ahead of print].
140. Valer P., Paul B., Eugenia B., et al. Annexin A5 as independent predictive biomarker for subclinical atherosclerosis and endothelial dysfunction in systemic lupus erythematosus patients. Clin Lab 2013, 59(3-4):359-367.
141. Perna M., Roman M.J., Alpert D.R., et al. Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patients. Arthritis Rheum 2010, 62(6):1718-1722.
142. Santos M.J., Pedro L.M., Canhao H., et al. Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. Atherosclerosis 2011, 219(2):821-826.
143. Rho Y.H., Chung C.P., Oeser A., et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. JRheumatol 2008, 35(9):1789-1794.
144. Parra S., Cabre A., Marimon F., et al. Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients. Lupus 2014, 23(3):245-254.
145. Somers E.C., Zhao W., Lewis E.E., et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012, 7(5):e37000.
146. Lee P.Y., Li Y., Richards H.B., et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007, 56(11):3759-3769.
147. Ahmad H.M., Sarhan E.M., Komber U. Higher circulating levels of OxLDL % of LDL are associated with subclinical atherosclerosis in female patients with systemic lupus erythematosus. Rheumatol Int 2014, 34(5):617-623.
148. Romero F.I., Amengual O., Atsumi T., et al. Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol 1998, 37(8):883-888.
149. Hayem G., Nicaise-Roland P., Palazzo E., et al. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001, 10(5):346-351.
150. Su J., Frostegard A.G., Hua X., et al. Low levels of antibodies against oxidized but not nonoxidized cardiolipin and phosphatidylserine are associated with atherosclerotic plaques in systemic lupus erythematosus. JRheumatol 2013, 40(11):1856-1864.
151. Anania C., Gustafsson T., Hua X., et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010, 12(6):R214.
152. Nikpour M., Urowitz M.B., Gladman D.D. Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep 2009, 11(4):248-254.
153. Gustafsson J., Gunnarsson I., Borjesson O., et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther 2009, 11(6):R186.